Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AsiaMedicSGX:505 Return-on-Tangible-Equity is 27.46% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, AsiaMedic ranks better than 69.47% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. AsiaMedic's annualized net income for the quarter that ended in Dec. 2025 was S$4.12 Mil. AsiaMedic's average shareholder tangible equity for the quarter that ended in Dec. 2025 was S$15.02 Mil. Therefore, AsiaMedic's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 27.46%.
The historical rank and industry rank for AsiaMedic's Return-on-Tangible-Equity or its related term are showing as below:
SGX:505'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -83.31 Med: -3.77 Max: 22.8
Current: 13.69
During the past 13 years, AsiaMedic's highest Return-on-Tangible-Equity was 22.80%. The lowest was -83.31%. And the median was -3.77%.
SGX:505's Return-on-Tangible-Equity is ranked better than 69.47% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.32
vs SGX:505: 13.69
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
AsiaMedic Return-on-Tangible-Equity Related Terms
AsiaMedic Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for AsiaMedic's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:505 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, AsiaMedic's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AsiaMedic Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, AsiaMedic's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where AsiaMedic's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 27.46% mean?
AsiaMedic (SGX:505) has a Return-on-Tangible-Equity of 27.46% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AsiaMedic and its competitors. According to the industry distribution chart, AsiaMedic ranks #58 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 30.5%.
Is AsiaMedic's Return-on-Tangible-Equity too high?
AsiaMedic's current Return-on-Tangible-Equity is 27.46%. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.32. AsiaMedic's value of 27.46% is 8481.3% above this industry median. Based on the distribution chart, AsiaMedic ranks #58 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does AsiaMedic's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, AsiaMedic ranks #58 out of 190 companies for Return-on-Tangible-Equity. This puts AsiaMedic in the upper half of its industry. The industry median Return-on-Tangible-Equity is 0.32. AsiaMedic's value of 27.46% is 8481.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.32, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AsiaMedic's current Return-on-Tangible-Equity of 27.46% is 8481.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AsiaMedic and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AsiaMedic's current Return-on-Tangible-Equity is 27.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AsiaMedic stock overvalued right now?
Based on GuruFocus' analysis, AsiaMedic (SGX:505) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.02, compared to a current price of S$0.02 — trading 15% above its estimated fair value. The current Return-on-Tangible-Equity is 27.46% and 8481.3% above the Medical Diagnostics & Research industry median of 0.32. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For AsiaMedic (SGX:505), the current Return-on-Tangible-Equity is 27.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AsiaMedic Ltd is an investment holding company. The principal activities of the company include the provision of management services. It engaged in the business of operating medical clinics in Singapore. It generates revenue from health screening and medical wellness services, diagnostic imaging and radiology services, primary care services and sales of pharmaceutical products, and medical aesthetic services and related products, net of discounts.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:505 has been successfully added to your 
